Best Immunotherapy Companies in Sweden
The 34 best Immunotherapy companies in Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Anocca.
- ResearchAndMarkets.com
- The Business Research Company
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Sweden
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Anocca Deevloper of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases | $120M | 14 mo ago | 100 | — | — | — | — |
| 2 | ITBMed Developer of monoclonal antibodies to prevent transplant rejections | $87M | 58 mo ago | 28 | David Sachs Co-Founder | — | — | — |
| 3 | InDex Pharmaceuticals DNA-based immunomodulatory sequence medication for the treatment of inflammtatory bowel disease. | $45M | 85 mo ago | 7 | — | — | 251 patents Rectal and oral nucleic‑acid therapies for ulcerative colitis and related IBD | — |
| 4 | Affibody Developer of antibody mimetic and protein based drug for the treatment of multiple diseases | $43M | 46 mo ago | 113 | — | — | 422 patents Engineered affinity proteins (affibodies) targeting immune and cancer biomarkers for therapeutics | — |
| 5 | Asgard Therapeutics Developer of cancer immunotherapeutic solutions based on direct cell reprogramming | $40M | 31 mo ago | 7 | Cristiana Pires Co-Founder & CEO | — | 36 patents Immune cell reprogramming to dendritic and CDC1 cells for therapeutic vaccines | — |
| 6 | XNK Therapeutics Developer of cell-based immunotherapy for the treatment of cancer | $14M | 54 mo ago | 35 | Johan Liwing CEO | — | 10 patents NK cell expansion methods for immunotherapy and related medical applications | — |
| 7 | Diamyd Medical Developer of therapies for the treatment and prevention of autoimmune diabetes | $13M | 94 mo ago | 46 | Ulf Hannelius President & CEO | 3 signals ▼50% Leadership | 113 patents Personalized immunotherapy and peptide vaccines for diabetes based on genetic stratification | — |
| 8 | Oblique Therapeutics Developer of antibodies and small molecules for the treatment of advanced and metastatic cancer | $12M | 71 mo ago | 23 | — | — | 126 patents TRPV1-targeted antibodies/epitopes and sulfonyl‑pyridine small‑molecule cancer therapeutics | — |
| 9 | Alligator Bioscience Developer of antibody-based immunotherapies for the treatment of cancer | $10M | 96 mo ago | 61 | — | — | 316 patents Engineered antibody and polypeptide immunotherapies, especially CD40‑targeted combination treatments | — |
| 10 | Strike Pharma Developer of immuno therapeutics to treat cancer | $6M | 56 mo ago | 10 | Marten Winge Chief Executive Officer | — | 31 patents Bispecific protein therapeutics and fusion polypeptide‑lipid nanoparticle delivery platforms | — |
| 11 | 2A Pharma Developing vaccine using adeno-associated virus-like particle technology for cancer and infectious diseases. | $5M | 100 mo ago | 10 | Preben Bruun-Nyzell CEO | — | 10 patents Therapeutic parvovirus protein vectors for autoimmune and HPV diseases | — |
| 12 | Idogen Developer of tolerogenic vaccines that reprogram the immune system | $3M | 109 mo ago | 6 | — | — | 42 patents IDO pathway modulation for immuno‑oncology using epigenetic agents and novel therapeutics | — |
| 13 | Lipum Developer of antibody to treat juvenile idiopathic arthritis | $3M | 70 mo ago | 5 | Lennart Lundberg Co-Founder | — | 23 patents Therapeutic anti-BSSL antibodies for oncology applications | — |
| 14 | Athera Biotechnologies Developing MAb and a companion diagnostic kit for cardiovascular diseases | $3M | 130 mo ago | 4 | — | — | 140 patents Drug-eluting stent coatings with annexin A5 and anti‑phosphorylcholine antibody therapeutics | — |
| 15 | Abera Bioscience Early stage vaccine development company using a platform based on Gram-negative bacteria and derived Outer… | $2M | 59 mo ago | 6 | Maria Alriksson CEO | — | 31 patents Bacterial outer‑membrane vesicle display platforms for vaccines and cell‑free protein production | — |
| 16 | Cantargia Developer of antibody-based therapy for the treatment of solid tumors and cancers | $1M | 70 mo ago | 43 | Göran Forsberg CEO | 9 signals ▲50% Leadership · Announcements · M&A | 113 patents IL1RAP-targeted antibody therapeutics for cancer treatment | — |
| 17 | AAX Biotech Developer of immunotherapies for cancer and autoimmune therapies | $685K | 8 mo ago | — | Maria Knudsen CEO | — | 2 patents Protein engineering and design of therapeutic agents and their binding sites | — |
| 18 | Lead Biologics Developer of therapeutic antibodies against cancer | $259K | 14 mo ago | — | Thoas Fioretos Co-Founder | — | 5 patents Therapeutic antibody engineering and related biomedical applications | — |
| 19 | Genagon Therapeutics Developing antibodies for the treatment of cancer and inflammatory diseases | $233K | 129 mo ago | 10 | Simon Fredriksson Founder & CEO | — | 20 patents Patents concentrated in health & consumer products | — |
| 20 | Alzinova Early-stage, public, Swedish Biotech company developing oligomer-directed vaccine and mAbs for Alzheimers'… | $164K | 109 mo ago | 4 | Anders Sandberg Co-Founder | — | 24 patents Humanized antibodies and immunization methods targeting amyloid‑beta 42 for Alzheimer’s therapy | — |
Top 12 Immunotherapy companies in Sweden
#1
Series D · Sodertalje, Stockholm County · founded 2014 · 100 employees$120Mraised▾
Developer of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases. The company has TCR-modified T-cell therapies against multiple antigen classes, tumours, genetic mutations, and viruses that cause cancer. The proprietary Immuno-technology platform for its target discovery, validation, and product development.
- Aug 2025Series D$46M
- May 2023Series C$36.9M
- Dec 2022Venture Debt$26.5M
- Jul 2021Series B$47M
#2
Seed · Stockholm, Stockholm County · founded 2020$684.9Kraised▾
Developer of immunotherapies for cancer and autoimmune therapies. It offers Seqitope an antibody epitope mapping method, Opti-mAb for CAR-T cells, and bispecific antibodies development for cancer treatment.
- Feb 2026Seed—
- Oct 2024Seed$684.9K
#3
Series A · Lund, Skane County · founded 2017 · 7 employees$39.8Mraised▾
Developer of cancer immunotherapeutic solutions based on direct cell reprogramming. The company has developed TrojanDC cancer immunotherapy by using dendritic cell reprogramming that has anti-tumor immunity power to suppress T-cell responses to cancers. It uses gene therapy-based technology that allows cancer cells to be immunogenic & unleashes the immune system against cancer.
- Mar 2024Series A$32.8M
- Jul 2023Grant (prize money)$81.9K
- Nov 2021Seed$6.9M
- May 2020Grant (prize money)$55.5K
#4
Seed · Lund, Skane County · founded 2022$259.2Kraised▾
Developer of therapeutic antibodies against cancer. It offers recombinant antibody technology to enhance immunotherapy which includes LB01 novel target for checkpoint inhibition in leukemia and solid tumors, LB02 target selectively expressed on leukemic cells, and LB03 an innate immune checkpoint inhibitor.
- Aug 2025Seed$259.2K
#5
Series A · Stockholm, Stockholm County · founded 2016 · 28 employees$87Mraised▾
Developer of monoclonal antibodies to prevent transplant rejections. The company is developing a humanized IgG1K antibody, Siplizumab which targets human CD2 molecules. The antibody binds to the human CD2 receptor found on T lymphocytes (T cells), natural killer cells, and thymocytes to inhibit their activation. The lead candidate Siplizumab is in the pivotal stage of the clinical trial for solid organ transplantation, and bone marrow transplantation.
- Dec 2021Series A$20M
- Apr 2018Angel$67M
#6
Series D · Solna, Stockholm County · founded 1998 · 113 employees$43.3Mraised▾
Developer of antibody mimetic and protein based drug for the treatment of multiple diseases. Its proprietary technology platforms are Affibody molecules is used for developing antibody mimetics monoclonal antibodies and antibody fragments. The leading candidate of the company is for prevention of Alzheimers disease, autoimmune diseases, and psoriasis, along with diagnostic imaging program for metastatic breast cancer.
#7
Public · Stockholm, Stockholm County · founded 2000 · 7 employees$45.4Mraised▾
InDex Pharmaceuticals develops drugs for the treatment of ulcerative colitis. It offers Kappaproct, a DNA-based immunomodulatory sequence medication (TLR Agonists) that provides a local anti-inflammatory effect leading to healing of the mucosa and improvement of clinical symptoms for patients with severe ulcerative colitis; and DiBiCol, a diagnostic test that differentiates between ulcerative colitis and Crohn’s disease, the two major forms of inflammatory bowel disease.
- Sep 2019PE$14.1M
- Aug 2018Grant (prize money)$58.4K
- Mar 2017Grant (prize money)$200.6K
- Sep 2016Post IPO$14.4M
#8
Series B · Huddinge, Stockholm County · founded 2012 · 35 employees$13.9Mraised▾
Developer of cell-based immunotherapy for the treatment of cancer. The company’s platform technology and leading autologous drug candidate, CellProtect, has ideal properties for targeting cancer. The product pipeline inlcudes ACP - 001 and ISA-HC-NK.
- Mar 2022Series B$13.9M
#9
Series A · Gothenburg, Vastra Gotaland County · founded 2015 · 23 employees$11.7Mraised▾
Oblique Therapeutics is a developer of antibodies and small molecules for the treatment of advanced and metastatic cancer. The company's drugs are based on two platforms that are proprietary antibody platform for functional antibodies, and metabolic cytotoxics with immunomodulatory potential. It's lead functional antibodies are against TRPV1 and TRPV2 for the treatment of inflammatory/idiopathic pain and metastatic cancer.
- Nov 2020Series A$11.4M
- Dec 2015Seed$296.9K
#10
Seed · Uppsala, Uppsala County · founded 2020 · 10 employees$6Mraised▾
Developer of immunotherapeutics to treat cancer. The company is focusing on the development of immunotherapy solutions for the treatment of solid tumors by using proprietary ADAC technology which is known as Immune Gas Pedal (IMMGAP) technology.
- Feb 2022Seed$4.8M
- Jun 2021Seed$1.2M
#11
Public · Stockholm, Stockholm County · founded 1994 · 46 employees$12.8Mraised▾
Developer of therapies for the treatment and prevention of autoimmune diabetes. It is developing therapeutic diabetes vaccine Diamyd, an antigen-specific immunotherapy for the preservation of endogenous insulin production. It also develops the GABA-based investigational drug Remygen as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia.
- Dec 2018Post IPO$6.5M
- Sep 2011Grant (prize money)$3M
- Nov 2009Grant (prize money)$1.8M
- Dec 2006Post IPO$1.5M
#12
Public · Lund, Skane County · founded 2001 · 61 employees$10Mraised▾
Developer of antibody-based immunotherapies for the treatment of cancer. The proprietary technology platforms include the human antibody library ALLIGATOR-GOLD and the protein optimization technology FIND. The pipeline consists of ADC-1013 a CD40 agonistic human monoclonal antibody, ADC-1015 is a bispecific antibody directed towards OX40 and CTLA-4 and ADC-1016 is a bispecific immuno-oncology.
- Oct 2018Grant (prize money)$55K
- Oct 2015Series A$10M
Funding & investor landscape
Notable founders
How research on Immunology & Immunotherapy is moving in Sweden
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 511 Sweden-affiliated papers.
- Karolinska Institutet156
- Karolinska University Hospital111
- Ludwig Cancer Research75
- Lund University55
- Uppsala University52
- Immune system4→55
- Cancer immunotherapy1→12
- T cell2→12
- Antigen4→14
- Tumor microenvironment1→10
- Immune system8→72
- Disease1→26
- Cancer2→20
- Oncology1→19
- Tumor microenvironment3→19
- Immune system5→20
- Disease3→15
- Cancer3→9
- Autoimmune disease2→8
- Internal medicine1→7
Where immunology is researched across Sweden
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.